Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Trending topics among doctors today!
Trending topics among doctors today!
The FDA has issued an update to the ciltacabtagene autoleucel (CARVYKTI) label describing secondary AML/MDS in 10% of patients treated on CARTITUDE-1 (10/97). CARTITUDE-1 is a Phase IB/II trial that evaluated ciltacabtagene autoleucel (CARVYKTI) in patients with relapsed of refractory…
In a cross-sectional study of 2775 patients with colorectal cancer from 2011 to 2016, decreased use of neoadjuvant radiotherapy (87% to 37%) was not associated with changes in 4-year local recurrence (5.8% vs 5.5%) in patients with lower risk rectal…
177Lu-PNT2002 met its primary endpoint of radiographic progression-free survival (rPFS) in the pivotal Phase III SPLASH trial (9.5 months vs 6.0 months, HR 0.71), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor…
